ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S ...

Acadia Pharmaceuticals has scored a second court win in less than a month that protects patents for its Parkinson's Disease treatment Nuplazid. The biopharmaceutical company said Monday that a federal ...

Across the recent three months, 11 analysts have shared their insights on ACADIA Pharmaceuticals ACAD, expressing a variety ...

Acadia Pharmaceuticals (NASDAQ: ACAD) announced that the U.S. Court of Appeals has upheld the validity of its patent for ...

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 26.1% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) rallied 26% after the company secured another court win that further solidified Nuplazid’s intellectual property position. The stock is now back to ...

Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials ...

Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, ...